M&A Trends in Pharma - Q4 2024
Summary
This report analyzes the merger and acquisition (M&A) activity in Q4 2024 in the Pharma sector.
The global pharma sector in Q4 2024 witnessed deals worth $18.5 billion, a decline of 31.9% compared to Q3 2024. In terms of deal volume, there was a rise of 7.5% to 144 M&A deals in Q4 2024. Oncology was the top therapy area with 51 deals, an increase of 4.1% YoY compared to 2023.
Scope
- This report provides an overview of M&A activity globally in Q4 2024 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q4 2024 in the Pharma sector.
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Pharma M&A Activity in Q4 2024
- 2.1 Pharma Insights: Deal spotlight
- 3 Global M&A Trends in Pharma
- 4 Global Quarterly M&A Activity in Pharma
- 5 Ownership Type: Private Vs Public (Count)
- 6 Ownership Type: Private Vs Public (Value)
- 7 Global M&A Activity in Pharma by Deal Size
- 8 Notable Pharma Deals in Q4 2024
- 9 Pharma Regional Comparison - Q4 2024
- 10 Global Cross Border M&A Trends in Pharma
- 11 Inbound and Outbound Deals in Pharma in Q4 2024
- 12 Regional M&A Activity in Pharma by Value and Volume
- 13 Pharma M&A Review by Top 10 Countries
- 14 Top 10 Therapy Area M&A Review
- 16 Further Information
- 16.1 Methodology
- 17 Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook